These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 32245912)

  • 1. Comparison of single and dual latent tuberculosis screening strategies before biologic and targeted therapy in patients with rheumatic diseases: a retrospective cohort study.
    Tang I; So H; Luk L; Wong V; Pang S; Lao V; Yip R
    Hong Kong Med J; 2020 Apr; 26(2):111-119. PubMed ID: 32245912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents.
    Kim JH; Won S; Choi CB; Sung YK; Song GG; Bae SC
    Int J Rheum Dis; 2015 Mar; 18(3):315-22. PubMed ID: 25351815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases.
    Lee CK; Wong SHV; Lui G; Tang W; Tam LS; Ip M; Hung E; Chen M; Wu JC; Ng SC
    J Crohns Colitis; 2018 Jul; 12(8):954-962. PubMed ID: 29757355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chest roentgenography is complementary to interferon-gamma release assay in latent tuberculosis infection screening of rheumatic patients.
    Wang PH; Lin CH; Chang TH; Wu CS
    BMC Pulm Med; 2020 Aug; 20(1):232. PubMed ID: 32867745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of a commercial interferon-gamma release assay and tuberculin skin test for the detection of latent tuberculosis infection in Hong Kong arthritis patients who are candidates for biologic agents.
    So H; Yuen CS; Yip RM
    Hong Kong Med J; 2017 Jun; 23(3):246-50. PubMed ID: 28126971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Study of Optimal Screening for Latent Tuberculosis in Patients with Inflammatory Bowel Disease.
    Al-Taweel T; Strohl M; Pai M; Martel M; Bessissow T; Bitton A; Seidman E; Afif W
    Dig Dis Sci; 2018 Oct; 63(10):2695-2702. PubMed ID: 29968143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tuberculosis screening among HIV-infected patients: tuberculin skin test vs. interferon-gamma release assay.
    Adams JW; Howe CJ; Andrews AC; Allen SL; Vinnard C
    AIDS Care; 2017 Dec; 29(12):1504-1509. PubMed ID: 28486818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon gamma release assay tests are associated with persistence and completion of latent tuberculosis infection treatment in the United States: Evidence from commercial insurance data.
    Stockbridge EL; Loethen AD; Annan E; Miller TL
    PLoS One; 2020; 15(12):e0243102. PubMed ID: 33270737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida.
    Medina-Gil C; Dehesa L; Vega A; Kerdel F
    Int J Dermatol; 2015 Jul; 54(7):846-52. PubMed ID: 26108266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening and Treatment of Latent Tuberculosis Among Patients Receiving Biologic Agents: A National and International Survey of Rheumatologists.
    Tran NQ; Garcia-Rosell M; Pattanaik D; Raza SH; Carbone L
    J Clin Rheumatol; 2017 Jan; 23(1):6-11. PubMed ID: 28002150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-γ release assay as a sensitive diagnostic tool of latent tuberculosis infection in patients with HIV: a cross-sectional study.
    Klautau GB; da Mota NVF; Salles MJC; Burattini MN; Rodrigues DS
    BMC Infect Dis; 2018 Nov; 18(1):585. PubMed ID: 30453903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic review: agreement between the latent tuberculosis screening tests among patients with rheumatic diseases.
    Pyo J; Cho SK; Kim D; Sung YK
    Korean J Intern Med; 2018 Nov; 33(6):1241-1251. PubMed ID: 29277097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
    Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
    Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model.
    Tasillo A; Salomon JA; Trikalinos TA; Horsburgh CR; Marks SM; Linas BP
    JAMA Intern Med; 2017 Dec; 177(12):1755-1764. PubMed ID: 29049814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings?
    Palacios CF; Chowdhary V; Hao R; Danve A; Malinis M
    PLoS One; 2024; 19(7):e0306337. PubMed ID: 38959249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening of latent tuberculosis infection among health care workers working in Hajj pilgrimage area in Saudi Arabia, using interferon gamma release assay and tuberculin skin test.
    Bukhary ZA; Amer SM; Emara MM; Abdalla ME; Ali SA
    Ann Saudi Med; 2018; 38(2):90-96. PubMed ID: 29620541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for latent tuberculosis infection among patients with rheumatoid arthritis in the era of biologics and targeted synthetic disease-modifying anti-rheumatic drugs in India, a high-burden TB country: The importance of Mantoux and Quantiferon-TB Gold tests.
    Malaviya AN; Aggarwal VK; Rawat R; Baghel S; Thakran R; Zaheer Q; Garg S; Kapoor S
    Int J Rheum Dis; 2018 Aug; 21(8):1563-1571. PubMed ID: 29345081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superiority of Interferon Gamma Assay Over Tuberculin Skin Test for Latent Tuberculosis in Inflammatory Bowel Disease Patients in Brazil.
    Amorim RF; Viegas ERC; Carneiro AJV; Esberard BC; Chinem ES; Correa RS; Rodrigues L; Ribeiro-Alves M; Silva KS; de Souza HS; Carvalho ATP
    Dig Dis Sci; 2019 Jul; 64(7):1916-1922. PubMed ID: 30673986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γ release assays under real-life conditions.
    Kleinert S; Tony HP; Krueger K; Detert J; Mielke F; Rockwitz K; Schwenke R; Burmester GR; Diel R; Feuchtenberger M; Kneitz C
    Ann Rheum Dis; 2012 Nov; 71(11):1791-5. PubMed ID: 22586160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing the cost-effectiveness of two screening strategies for latent tuberculosis infection in Portugal.
    Sousa S; Rocha D; Silva JC; Ribeiro AI; Gonçalves G; Almeida Á; Correia AM; Duarte R; Carvalho C
    Pulmonology; 2021; 27(6):493-499. PubMed ID: 34053903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.